What T2 Biosystems, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Elsbree David B | Director | Sep 13 | Open-market sale · S | −55 | $2.42 | −$133 | 23 |
| Capital Royalty L.p. | 10% owner | May 09 | Derivative Conversion · C | +108,752 | — | — | 4,704,729 |
| Capital Royalty L.p. | 10% owner | May 09 | Derivative Conversion · C | +1,716,048 | — | — | 4,595,977 |
| Capital Royalty L.p. | 10% owner | May 03 | Grant / award · A | +2,001,514 | — | — | 2,879,929 |
| Capital Royalty L.p. | 10% owner | May 03 | Grant / award · A | +1,565,445 | — | — | 3,548,707 |
| Capital Royalty L.p. | 10% owner | May 03 | Grant / award · A | +129,629 | — | — | 266,038 |
| Capital Royalty L.p. | 10% owner | May 03 | Grant / award · A | +403,608 | — | — | 828,324 |
| Capital Royalty L.p. | 10% owner | May 03 | Grant / award · A | +648,139 | — | — | 1,330,175 |
| Capital Royalty L.p. | 10% owner | Apr 12 | Grant / award · A | +390,142 | — | — | 878,415 |
| Capital Royalty L.p. | 10% owner | Apr 12 | Grant / award · A | +1,647,315 | — | — | 1,983,262 |
| Capital Royalty L.p. | 10% owner | Apr 12 | Grant / award · A | +136,409 | — | — | 136,409 |
| Capital Royalty L.p. | 10% owner | Apr 12 | Grant / award · A | +424,716 | — | — | 424,716 |
| Capital Royalty L.p. | 10% owner | Apr 12 | Grant / award · A | +682,036 | — | — | 682,036 |
| Gibbs Michael Terrence | General Counsel | Feb 24 | Exercise / conversion · M | +29 | — | — | 135 |
| Sperzel John J Iii | See Remarks | Feb 24 | Exercise / conversion · M | +67 | — | — | 400 |
| Sprague John M | Chief Financial Officer | Feb 24 | Exercise / conversion · M | +29 | — | — | 141 |
| Giffin Brett A. | Chief Commercial Officer | Feb 20 | Exercise / conversion · M | +13 | — | — | 77 |
| Sperzel John J Iii | See Remarks | Feb 20 | Exercise / conversion · M | +160 | — | — | 333 |
| Sprague John M | Chief Financial Officer | Feb 20 | Exercise / conversion · M | +40 | — | — | 112 |
| Gibbs Michael Terrence | General Counsel | Feb 20 | Exercise / conversion · M | +40 | — | — | 106 |
Loading...
